Search results
Allozymes Raises $15 Million in Series A Funding, Poised to Revolutionize Industries with Enzymatic...
The Yuma Sun· 1 day agoAdditionally, the funding will fuel the development of the industry's most comprehensive enzyme data...
CTT Pharmaceutical Holdings CEO acquires $380 in shares By Investing.com
Investing.com· 7 days agoIn a recent move at CTT Pharmaceutical Holdings, Inc. (OTCMKTS:CTTH), the company's CEO has made a...
IP Risks from AI’s Role In Drug Discovery | Law.com
Law.com· 7 days agoDrug discovery involving artificial intelligence (AI) tools has quickly occupied significant territory in the pharmaceutical industry ...
Breaking Barriers in Bioprocessing: An Interview with Himanshu Gadgil, CEO of Enzene Biosciences
BioPharma-Reporter· 1 day agoWith a rich background in biochemistry and extensive experience in the pharmaceutical industry,...
Idea Fund of La Crosse raises $31.5 million for another venture capital fund in Upper Midwest
Gannett via AOL· 3 hours agoThe 2-year-old company has clients in the manufacturing of food and beverage products, consumer...
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks...
Benzinga· 2 days agoRXRX Price Action: Recursion Pharmaceutical shares closed at $9.48 on Monday, reflecting an impressive gain of 10.2% compared to the previous day’s close, according to...Recursion ...
...Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals...
Benzinga· 20 hours agoKey states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham...
AI will not magically solve business challenges. It’s time to re-shape the narrative
Euronews via Yahoo News· 2 days agoThe right AI solutions are out there for businesses. It’s just about identifying them and...
Immix Biopharma CEO buys $9.7k in company stock By Investing.com
Investing.com· 12 hours agoImmix Biopharma Inc.'s CEO and Chairman, Ilya M. Rachman, has recently increased his investment in...
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly
CNBC· 5 days agoIn a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed...